<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000761967"><TermName>PAD regimen</TermName><TermPronunciation>(... REH-jih-men)</TermPronunciation><TermDefinition><DefinitionText>An abbreviation for a chemotherapy combination used to treat multiple myeloma. It includes the drugs bortezomib, doxorubicin (Adriamycin), and dexamethasone. Also called PAD.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000764481" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;PAD regimen&quot;" language="en" id="_3"/><MediaLink ref="CDR0000764482" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen PAD&quot;" language="es" id="_4"/><SpanishTermName>régimen PAD</SpanishTermName><SpanishTermDefinition><DefinitionText>Abreviatura de una combinación de quimioterapia que se usa para tratar el mieloma múltiple e incluye los medicamentos bortezomib, doxorrubicina (Adriamycin) y dexametasona. También se llama PAD.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2014-06-12</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000762155">PAD</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
